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between 2005 and the 30th of June 2010. We observed their administrative path.
Among those available in the first teaching hospital group in France (42 hospitals),
we evaluated the potential variables associated with the unit price growth rate
before and after MA. RESULTS: During the study period, 77 ATUs obtained a MA,
mostly after a European approval. Cancer represented the major therapeutic area
with 21 drugs. After MA, 9 previous ATUs (12%) were not considered by the High
commission for health (HAS) to have neither major nor important medical benefit
and 19 (25%) were not supposed to bring some benefits compared to existing ther-
apies. For the price growth rate’s analysis, 57 drugs were retrieved (9 previous free
ATUs were excluded): 68.4% had a decreasing price after MA whereas 17.5% in-
creased and 14% were stable. Overall mean price growth rate was -12.1%  22.6%.
The improvement in medical benefit assessed by HAS was not a predictor of the
growth rate (p0.392). CONCLUSIONS: From these results, pharmaceutical compa-
nies seem marketing these compassionate drugs, for which the benefit/risk ratio is
only presumed, at a price that guarantees a margin for future negotiations.
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OBJECTIVES:An inspection system that controls the prescription of specific groups
of pharmaceutical products exits in Spain. It requires certain prescriptions to be
authorized by a medical inspector. Traditionally, it has been carried out manually.
Currently, the implementation of an electronic system has modified the whole
process of prescription and dispensation of medicines countrywide. This study
aims to explore health care professionals’ views on the impact of the implemen-
tation of an electronic system on the prescription and dispensation of specifically
controlled medicines in the country. METHODS: Observational, exploratory, two
phases study. This abstract reports on phase 1 that included a literature review, a
review of current legislation, and telephone, audio-tape recorded semi-structured
interviews with primary care physicians, endocrinologists, pharmacists, medical
inspectors and regional health authorities from urban and rural areas across coun-
try until data saturation. A content analysis of interview transcriptions was con-
ducted. Data triangulation was performed. RESULTS: A total of 58 interviews were
conducted (21 primary care physicians, 11 endocrinologists, 6 pharmacists, 9 med-
ical inspectors, 11 health authority representatives). Three mechanisms for autho-
rizing the prescription of specifically controlled medicines exist across regions:
manual, electronic, and linked to electronic dispensation. The electronic system
speeds up the process and favors that the prescription of treatments more strictly
adjust to the clinical condition they have been authorized for. From health author-
ities’ and medical inspectors’ perspective, the inspection of prescription contrib-
utes to avoiding medicines misuse. From the physicians’ view, the inspection sys-
tem mostly serves to control the spending on medicines. Alternative strategies
based on professional training and education would more effectively contribute to
preventing treatments mishandling. CONCLUSIONS: Electronic mechanisms for
authorizing the prescription and dispensation of specifically controlled medicines
vary across regions. Differences on the perceived ultimate value of the inspection
system exist amongst physicians, medical inspectors and health authorities.
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OBJECTIVES: Health care spending has risen steadily in most countries, becoming
a concern for decision-makers worldwide. Commentators often point to the diffu-
sion of new medical technology as a key driver for burgeoning expenditures. This
paper critically appraises this conjecture, based on an analysis of existing litera-
ture, with the aim of offering a more detailed and considered analysis of the impact
of technological innovation on spending. METHODS: Key databases (e.g., PubMed,
EMBASE) were searched to identify relevant literature. Several categories of studies
(e.g., multivariate analyses, policy analyses) were included to cover different per-
spectives and issues regarding the relationship between medical technology and
costs. Applicable abstracts were identified and selected articles reviewed. A stan-
dardised template was developed to extract relevant information from the select
literature, which was then analysed for key themes across: impact of technology on
costs, factors influencing this relationship, and noted methodological challenges in
measuring such linkages. RESULTS: A total of 150 studies were reviewed. The
analysis suggests that the relationship between medical technology and spending
is complex and often conflicting. Study conclusions were often contingent on vary-
ing contextual factors, such as the sector examined, availability of other interven-
tions, population trends, and the methodological approach employed. Moreover,
the impact of medical technologies on costs differed across technologies; some
(e.g., cancer drugs, invasive devices) had significant financial implications, while
others were cost-neutral or cost-saving. Several studies examined technology in
general, making it difficult to tease out the contribution of different types of
interventions. CONCLUSIONS: Ascertaining the impact of technological advances
on spending is difficult to quantify (and qualify). Issues of causality and incomplete
knowledge of the interactions between technology and other factors affecting ex-
penditures often constrain the reliability of analyses. We argue that it would be
more productive to ask if investments in medical technology result in better value
in health care.
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OBJECTIVES: This study assesses the evolution of international reference pricing
(IRP) across 34 countries, from 2006 to 2011. Its current influence on innovative drug
pricing in the leading five European Union (EU) markets was also considered.
METHODS: An international reference pricing matrix was created and reviewed to
see if the basket of countries referred by nations to price their pharmaceuticals had
changed. Pharmaceutical prices were also used to review 2011 prices of five ran-
domly selected innovative blockbuster molecules across EU-5 countries; the mol-
ecules in question were bevacizumab, adalimumab, etanercept, rosuvastatin and
infliximab.RESULTS:The EU-5 markets lead the reference basket used by countries
in their price setting process both in 2006 and 2011. Countries that reference these
markets are varied and not limited to economically similar markets both within
and outside the EU. While there have been additions and deletions, many countries
have largely maintained their reference basket of countries. Since 2006, more
emerging markets have become IRP prescribers. Unlike Brazil, and Turkey, which
followed IRP prior to 2006 and exclusively use developed country prices to price
their own products, the newer emerging market followers have also chosen to
include neighbouring countries and/or economically similar country prices in their
mechanism. A comparison of 2011 prices across the EU-5 markets showed less
price variation between countries that followed IRP compared to those that fol-
lowed free pricing, but prices were not necessarily lower. CONCLUSIONS: Coun-
tries using IRP still rely on EU-5 drug prices to price their medicines. However, new
adopters of the mechanism are including similar and neighbouring countries to
arrive at affordable rates and prevent parallel export. With more emerging markets
rolling out IRP, it is notable that in the absence of a set formula that identifies the
lowest prices, this technique is one of cost harmonization rather than cost contain-
ment.
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OBJECTIVES:We surveyed pharmaceutical prices in 18 countries (mix of developed
and emerging countries). The goal of the survey was to analyze and compare drug
prices in an attempt to determine the countries where drug pricing procedures are
more favorable or more stringent, as well as the countries where price cuts are
common and where price increases can still be expected. METHODS: The method-
ology was based on estimated ex-manufacturer pricing data from PharmOnLine
International, looking at current and historical drug prices in 18 countries. For each
country, all prescription drugs by average manufacturer prices were looked at, as
well as by therapeutic area. Several case studies were also analyzed. RESULTS:
With countries having their own legislation and standards when it comes to drug
pricing, significant price differentials are seen between countries. By far, condi-
tions are still most favorable in the US. Legislation is more restrictive in other
markets, notably in the European Union. Our data finds that the ongoing pricing
reform in Germany has already had a significant impact on drug prices, which are
dropping. Conditions are more attractive for innovative drugs in certain emerging
countries - including Brazil or Russia - where pharmaceutical companies are in-
creasingly investing as demonstrated with the large number of innovative drugs
marketed in those countries. Additionally, a significant number of case studies
demonstrate that innovative drugs are highly priced and that price increases can
still be expected in those countries. CONCLUSIONS: With stringent pricing legisla-
tions in developed countries, opportunities are now seen in emerging countries
where pharmaceutical companies increasingly invest. In these markets, the chal-
lenge is seen at the reimbursement and volume levels. Nevertheless, with govern-
ments enhancing their healthcare systems, the data points to the conclusion that
the basket of drugs funded will increase in the near future.
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OBJECTIVES: Indication expansion is a commonly utilized strategy to maximize
return on investment for novel pharmaceuticals. As orphan drug designation can
confer pricing, reimbursement and funding benefits, such indications can provide
attractive targets for launch or follow-on indications. We aim to understand how
expansions into or out of orphan indications affect a product’s total pricing and
reimbursement opportunity. METHODS: Centering our research on orphan indica-
tions, we explored three potential scenarios that could be reached when expanding
a products indication (from highest to lowest frequency of occurrence): 1) Orphan
(current) to Orphan (indication expansion); 2) Non-Orphan (current) to Orphan
(indication expansion); and 30 Orphan (current) to Non-Orphan (indication expan-
sion). We conducted analogue analysis across a variety of key global markets to
understand the implications on pricing and reimbursement for a product moving
between these groupings. RESULTS: The analogue analysis indication expansion
between orphan indications is relatively common, particularly in oncology. Expan-
sion in this way did not significantly impact product funding or access restrictions,
although pricing can be affected by the increased patient population size. Further-
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more, regulatory requirements stipulate that a new orphan status application
must be submitted for each indication. Under EMA regulations, orphan and non-
orphan indications cannot be granted under the same marketing authorization.
Although expansions between orphan and non-orphan indications are more com-
mon in the US, no examples of expansion from a non-orphan to orphan indication
were identified by the authors. CONCLUSIONS: While indication expansion be-
tween orphan indications is relatively common, examples of expansion into or out
of orphan indications are less frequent due to the regulatory restrictions. Pricing
and reimbursement dynamics in all cases are reflective of the trade-offs between
price potential and population size across indications.
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OBJECTIVES: Korea introduced a new positive list system in 2007 together with a
price negotiation procedure. Importantly, these two systems are run by two differ-
ent, independent organizations, namely the Health Insurance Review & Assess-
ment Service (HIRA) and the National Health Insurance Corporation (NHIC). HIRA
reviews the cost-effectiveness data in submissions and makes listing decisions,
then NHIC takes over and sets the reimbursement price via negotiations with
manufacturers. The aim of this study is to compare the difference in price after
cost-effectiveness appraisal by HIRA and price negotiation by NHIC, and to analyze
the factors that NHIC has considered to determine the reimbursement price.
METHODS: All 35 submissions made to the NHIC between August 2007 and June
2008 were reviewed. 19 submissions concluded with agreement, 15 failed and one
case was suspended. In this review only 15 cases of successful negotiations were
included. The level of the reimbursement price compared to the submitted price for
both essential drugs and non-essential ones and factors affecting the final price
were analyzed.RESULTS:The discrepancy between reimbursement price and cost-
effective price was about 12.3311.44% on average. For 3 essential drugs, the price
level was almost equal to the submitted price whereas the average level was 84.94
11.21% of the cost-effective price for non-essential drugs. The major factors af-
fecting negotiations to determine the final price were narrowed down to total cost
of substitutes, the foreign price, and the pharmaceutical budget impact.
CONCLUSIONS: Our findings have demonstrated that drug pricing within the new
environment has been done independently of cost-effectiveness appraisal. The
payer has exhibited limited bargaining power for essential drugs. Overall, 87.67% of
the cost-effective price was accepted during price negotiations, and the total cost of
substitutes, foreign prices and pharmaceutical budget impact were considered
equally when fixing the reimbursement price. A limitation of this study is that the
result may not be generalized because of insufficient cases.
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OBJECTIVES: Primary research is often only conducted in a limited number of key
markets despite a product being launched across a wider range of countries. In
order to understand the implications of research findings across geographies, mar-
kets can be grouped by common underlying factors. METHODS: Market segmenta-
tion frameworks were developed based on key decision drivers which can be ap-
plied at different points in a product lifecycle. Within each framework, markets can
be segmented in up to two domains to distinguish segments. In-depth secondary
research was conducted in EU27 markets to understand key pricing, reimburse-
ment, access and uptake processes. Qualitative analysis of these findings permit-
ted us to place markets in the segmentation framework, allowing extrapolation of
findings across similar markets. RESULTS: Markets can be segmented in several
domains, depending on areas of interest for the research in question. For example,
in the case of peri-launch segmentation, most new pharmaceuticals aim to secure
optimal pricing and reimbursement – therefore an understanding of similarities
and differences in these areas are of greatest interest. Markets can be assessed in
terms of HTA data requirement, degree of centralization of decision making, pric-
ing regulations (fixed vs. ‘free’ pricing) or pricing decision drivers. This approach
was applied to understanding market similarities for a novel, hospital adminis-
tered product in a rare disease area. All 27 EU markets were segmented by level of
price regulation into three groups: price set by manufacturer, price set through
negotiation or strict price regulation. Understanding pricing drivers in each group
allowed results from primary research undertaken in only 6 of these markets to be
used by the manufacturer in all EU27 markets. CONCLUSIONS: Applying these
conceptual frameworks to drive market segmentation, key similarities and differ-
ences between markets can be used to extrapolate findings from primary market
research, or determine what strategic options are applicable to a given market.
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OBJECTIVES: In 1994, in French health care system, a supplement status for am-
bulatory reimbursement drugs, called “exception drugs”, was established. This
status enables to reimburse only specified indications of particularly costly drugs.
In this study we analyze what characteristics a drug should possess in order to be
considered as an exception drug. METHODS: Included in the study, were drugs
that had status of “exception drugs” as of April 2011. The clinical (actual benefit,
improvement of actual benefit) and economic (amount reimbursed by National
Health Insurance) characteristics were collected from official and publicly available
websources, as well as supplement restrictions for prescription (any prescription
or only the first one must be accomplished by a hospital practitioner; prescription
must be accomplished by a specialist; or prescription requires specific following
during the treatment). RESULTS: As of April 2011, there were 56 “exception drugs”
in trade name and 30 in generic name. The drugs from 9 ATC classes level I were
presented; the most numerous were A16 (Other alimentary tract and metabolism),
H01 (Pituitary and hypothalamic hormones and analogues), B03 (Antianemic prep-
arations). Supplement restrictions for prescription was applied to 33 drugs. Some
“exception drugs” (10) had also the status of drugs financed out of DRG payment
system. Most of the drugs, 91.07% (51/56) had high level of actual benefit. Around
half of the “exception drugs”, 42.86% (24/56) had level of improvement in actual
benefit from I to III. In 2009, part of reimbursed amount of “exception drugs” was
7.73% from all reimbursed drugs, whereas in 2004 it was 2.85%. Interestingly, in
2009 four exception drugs constituted about 1% of the reimbursed amount each,
and 40 – less than 0.1%. CONCLUSIONS: The analyzed types of characteristics, both
economic and clinical, can be used as criteria for establishing the status of excep-
tion drug.
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OBJECTIVES: Generic competition is an effective cost-containment mechanism
that improves static efficiency and stimulates pharmaceutical innovation. No prior
study has empirically analysed the relative delays in adoption of generic competi-
tion within the OECD. This study aims to investigate how price regulations in the
OECD affect timing of generic adoption following the first global generic launch.
METHODS: Drawing upon data from 1999 to 2008, we estimate the impact of ex-
ante price and market size expectations on the probability of generic launch using
discrete-time duration modeling with cloglog and logit regressions. The economet-
ric strategy employs both parametric and non-parametric duration dependence
and includes controls for local generic competition, firm characteristics and mol-
ecule heterogeneity. RESULTS: Ex-ante profit expectations result in faster adop-
tion; both expected price and market size increase the probability of launch. Our
findings suggest that neither molecule nor firm characteristics have a significant
effect on generic adoption across different specifications.CONCLUSIONS: Evidence
indicates that regulation has a significant impact on timing of adoption; however,
generic competitors tend to follow a locally oriented strategy in contrast to re-
search-intensive pharmaceutical firms.
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OBJECTIVES: Biosimilars are predicted to reduce prices of biologicals. Among bio-
similars, epoetin alfa has the largest market penetration in Germany and Spain.
The aim of this study was to describe the political, technological, economical and
social factors that impact on epoetin alfa sales and price in both European coun-
tries, which greatly differ in their generic market size. METHODS: Revisions of
regulatory legislation and policies regarding biosimilars at country and European
levels have been conducted. Estimations of market shares in units for epoetin alfa
originator and biosimilars plus darbopoetin alfa, a second generation biological,
were calculated. Epoetin alfa pricing trend was followed. All data was extracted
from IMS MIDAS database, using standard units and ex-manufacturer price.
RESULTS: Both countries are under the same regulatory framework and have pol-
icies that promote generic penetration, although automatic biosimilar substitution
is banned. Price of first launched biosimilar was approximately 30% below origina-
tor price in both countries. In Germany, originator price decreased about 16% after
launch of second biosimilar, whereas in Spain, originator price trend have no
changes to date. Regarding originator market shares, they did not change after
launch of biosimilars in Spain, while in Germany marked reductions were observed
along with biosimilars market share increases. In Spain, market shares of darbo-
poetin alfa were reduced when epoetin alfa biosimilar sales started, but no changes
of the kind were documented in Germany. CONCLUSIONS: Although both coun-
tries face similar political and technological factors; in Spain, social and economi-
cal ones could negatively impact stakeholder perception. In this country, the in-
troduction of biosimilars do not modify market share of the originator despite it
has a price about 30% higher. In Germany, stakeholders pose minimum resistance
to biosimilars, as market share and price of originator are immediately reduced
after the entry of biosimilars.
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OBJECTIVES:Most OECD countries employ pricing controls to contain rising health
care expenditures. The recent financial crisis has resulted in further pressure to
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